文献速递慢性肾脏病

可溶性尿激酶型纤溶酶原激活物受体与肾功能受损:基于马尔默饮食与癌症研究人群

Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study.
PubMed 文献 · Kidney Int Rep · 2017-01-01

在马尔默饮食与癌症研究队列中,基线5381名参与者的血浆suPAR水平被量化,随访时计算eGFR。基线suPAR最高四分位组随访时平均eGFR显著低于最低四分位组(68 vs. 74 ml/min per 1.73 m2;P-trend = 4.3 × 10-7)。多变量回归中,suPAR每增加1个log转换后的标准差,与eGFR下降(P = 3.3 × 10-9)及 incident CKD(561例事件,OR = 1.25;95%CI 1.10-1.41)相关。平均随访19年,suPAR与因肾功能受损住院风险相关(HR = 1.49;95%CI 1.27-1.74)。

要点

  • 基线suPAR最高四分位组随访eGFR显著低于最低四分位组。
  • suPAR每增加1个log标准差,incident CKD风险OR为1.25。
  • suPAR与因肾功能受损住院风险HR为1.49。

核心结论

  • 在健康中年人群中,基线suPAR水平升高与eGFR长期下降、慢性肾脏病发病率增加及因肾功能受损住院风险显著相关。

研究设计与样本

  • 基于人群的马尔默饮食与癌症研究队列,基线(1991-1994)量化5381名参与者的血浆suPAR,基线及随访(2007-2012)测量肌酐并计算eGFR。

主要发现

  • suPAR最高四分位组随访平均eGFR为68 ml/min per 1.73 m2,最低四分位组为74 ml/min per 1.73 m2(P-trend = 4.3 × 10-7)。
  • 多变量回归中,suPAR(每1 SD增量log转换值)与eGFR下降相关(P = 3.3 × 10-9)。
  • suPAR与incident CKD相关(561例事件,OR = 1.25;95%CI 1.10-1.41)。
  • 平均随访19年,suPAR与因肾功能受损住院风险相关(HR = 1.49;95%CI 1.27-1.74)。

关键数值与推荐

  • incident CKD定义为随访时eGFR < 60 ml/min per 1.73 m2。

临床怎么用

  • 在普通人群中,suPAR可能作为识别肾功能下降高风险个体的生物标志物,但需进一步验证。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The soluble urokinase-type plasminogen activator receptor (suPAR) has recently been associated with a decline in kidney function and incidence of chronic kidney disease in patients with cardiovascular disease undergoing cardiac catheterization, yet little is known whether suPAR is associated with deterioration of kidney function in the general population. METHODS: In the population-based Malmö Diet and Cancer Study cohort, plasma levels of suPAR were quantified in 5381 participants at baseline (1991-1994), and creatinine was measured and used to calculate estimated glomerulus filtration rate (eGFR) at baseline and follow-up (2007-2012). Incident chronic kidney disease was defined as eGFR < 60 ml/min per 1.73 m2 at follow-up. RESULTS: Participants within the highest quartile of suPAR had a significantly lower mean eGFR at follow-up than those within the lowest quartile (mean 68 vs. 74 ml/min per 1.73 m2; P-trend = 4.3 × 10-7). In multivariate regression analysis, suPAR (per 1 SD increment of log-transformed suPAR) was associated with a decline in eGFR (P = 3.3 × 10-9) and incident chronic kidney disease (561 events, odds ratio = 1.25; 95% confidence interval, 1.10-1.41). Furthermore, we identified 110 cases of hospitalization due to impaired kidney function via linkage to national registers of inpatient and outpatient hospital diagnoses. During a mean follow-up time of 19 years, suPAR was associated with risk for hospitalization due to impaired kidney function (hazard ratio = 1.49; 95% confidence interval, 1.27-1.74) in multivariate Cox proportional hazard analysis. DISCUSSION: The increased suPAR level at baseline was associated with a significantly higher longitudinal decline in eGFR, higher incidence of chronic kidney disease, and hospitalization due to impaired kidney function in a cohort of healthy middle-aged participants.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Schulz CA, Persson M, Christensson A, et al. Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study. Kidney Int Rep. 2017. PMID: 28367534. doi:10.1016/j.ekir.2016.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。